Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis
- PMID: 3777036
- DOI: 10.1159/000167175
Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis
Abstract
To study aluminum-related bone disease, bone biopsies and serum biochemical measurements were done in 97 patients on maintenance dialysis and in 100 patients with mild to moderate renal failure. Bone histology, histochemical staining for aluminum and determination of bone aluminum content were done. Stainable bone aluminum was found in 50% of dialyzed patients and in 5% of nondialyzed patients. The finding of stainable bone aluminum in dialyzed patients was associated with high morbidity and mortality; it was not only seen in most patients with low turnover osteomalacia, but also in 47% of patients with mixed uremic osteodystrophy and in 1 patient with predominant hyperparathyroid bone disease. Patients with stainable aluminum had lower bone mass and decreased activity of bone-forming and -resorbing cells. Cumulative doses of aluminum-containing phosphate binders were a major risk factor. Aluminum in drinking water represents an additional risk factor. Neither serum biochemical tests nor single infusion of deferoxamine could be employed as diagnostic tools. Bone biopsies were the only means for diagnosis.
Similar articles
-
[Aluminum poisoning].Lijec Vjesn. 1989 Apr-May;111(4-5):164-9. Lijec Vjesn. 1989. PMID: 2671563 Review. Croatian.
-
Aluminum-related osteomalacia in renal-failure patients.Clin Pharm. 1985 Jul-Aug;4(4):434-9. Clin Pharm. 1985. PMID: 3899471 Review.
-
Clinical and histologic features of iron-related bone disease in dialysis patients.Am J Kidney Dis. 1991 May;17(5):551-61. doi: 10.1016/s0272-6386(12)80497-5. Am J Kidney Dis. 1991. PMID: 2024657
-
Deferoxamine test and PTH serum levels are useful not to recognize but to exclude aluminum-related bone disease.Nephron. 1992;61(2):151-7. doi: 10.1159/000186863. Nephron. 1992. PMID: 1630538
-
Stainable aluminum and not aluminum content reflects bone histology in dialyzed patients.Kidney Int. 1986 Nov;30(5):717-22. doi: 10.1038/ki.1986.246. Kidney Int. 1986. PMID: 2431192
Cited by
-
Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.Klin Wochenschr. 1991 Jan 22;69(2):59-67. doi: 10.1007/BF01666818. Klin Wochenschr. 1991. PMID: 2027271 Clinical Trial.
-
Aluminium accumulation and immunosuppressive effect in recipients of kidney transplants.BMJ. 1988 Dec 17;297(6663):1581-2. doi: 10.1136/bmj.297.6663.1581. BMJ. 1988. PMID: 3147082 Free PMC article.
-
[Aluminum toxicity].Klin Wochenschr. 1989 Dec 15;67(24):1221-8. doi: 10.1007/BF01745293. Klin Wochenschr. 1989. PMID: 2517313 Review. German.
-
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.Crit Rev Toxicol. 2014 Oct;44 Suppl 4(Suppl 4):1-80. doi: 10.3109/10408444.2014.934439. Crit Rev Toxicol. 2014. PMID: 25233067 Free PMC article.
-
Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure.J Clin Invest. 1987 Mar;79(3):754-61. doi: 10.1172/JCI112881. J Clin Invest. 1987. PMID: 3818947 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical